Document:

Exhibit 10.44
Loan Agreement
Party A: Xi Wen
ID No.: [***]
Party B: Senmiao Technology Limited
For Senmiao Technology Limited (hereinafter referred to as the “Company”), due to the operation needs of the Company and upon consensus through negotiation, Mr. Xi Wen provides the Company with interest-free loan to carry out relevant businesses.
		I.
	Loan amount: $500,000.00

		II.
	Loan term: six months, calculated from July 28, 2021. Party B may repay all or part of the loan in advance.

		III.
	Loan interest: this loan is an interest-free loan.

		IV.
	Loan purpose: it shall be used for daily operation of the company, and Party B shall not change the loan purpose.

		V.
	The loan shall be remitted to:

Account Name: Senmiao Technology Limited
Address: 1345 Avenue of the Americas, New York, NY 10105
Bank Name: Chase Bank
Swift Code:CHASUS33
Account number: [***]
		VII.
	If there are any disputes between both parties on the performance of the agreement, they shall solve them through friendly negotiation; if the negotiation fails, any party can file a lawsuit to Changsha People’s Court for solution.

		VIII.
	The agreement is in duplicate, with each party holding one copy respectively.

​
	​
	Party B: Senmiao Technology Limited 

	Party A: Xi Wen
	​

	​
	CFO: /s/ Xiaoyuan Zhang

	​
	​

	Signing date: July 28, 2021
	Signing date: July 28, 2021

	​
	​

	Signing place: Chengdu, Sichuan
	​

​Exhibit 10.45
Loan Agreement
Party A: Xi Wen
ID No.: [***]
Party B: Senmiao Technology Limited
For Senmiao Technology Limited (hereinafter referred to as the “Company”), due to the operation needs of the Company and upon consensus through negotiation, Mr. Xi Wen provides the Company with interest-free loan to carry out relevant businesses.
		I.
	Loan amount: $300,000.00

		II.
	Loan term: three months, calculated from August 17, 2021. Party B may repay all or part of the loan in advance.

		III.
	Loan interest: this loan is an interest-free loan.

		IV.
	Loan purpose: it shall be used for daily operation of the company, and Party B shall not change the loan purpose.

		V.
	The loan shall be remitted to:

Account Name: Senmiao Technology Limited
Address: 1345 Avenue of the Americas, New York, NY 10105
Bank Name: Chase Bank
Swift Code:CHASUS33
Account number: [***]
		VII.
	If there are any disputes between both parties on the performance of the agreement, they shall solve them through friendly negotiation; if the negotiation fails, any party can file a lawsuit to Changsha People’s Court for solution.

		VIII.
	The agreement is in duplicate, with each party holding one copy respectively.

​
	​
	Party B: Senmiao Technology Limited

	Party A: Xi Wen
	​

	​
	CFO: /s/ Xiaoyuan Zhang

	​
	​

	Signing date: August 17, 2021
	Signing date: August 17, 2021

	​
	​

	Signing place: Chengdu, Sichuan
	​

​Exhibit 10.1

 

Execution Version

 

AGREEMENT

 

THIS
AGREEMENT (this “Agreement”), dated as of July 14, 2022 (the “Effective Date”),
is entered into by and among Quoin Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 42127 Pleasant Forest
Ct, Ashburn, VA 20148 (“Quoin”), Quoin Pharmaceuticals Ltd. (formerly known as Cellect Biotechnology Ltd.), an Israeli
company, with headquarters located at Azrieli Center, Round Tower, 30th Floor, 132 Menachem Begin Blvd, Tel Aviv, 6701101 (the “Company”),
and the investor listed on the signature page attached hereto (the “Holder”). Quoin, the Company and the Holder
are referred to collectively herein as the “parties” and each as a “party.” Capitalized terms used herein and
not otherwise defined shall have the definitions ascribed to such terms in the Series A Warrant and/or Exchange Warrants, as applicable.

 

WHEREAS:

 

A.          Pursuant
to the Securities Purchase Agreement (as amended, the “Primary Financing SPA”) by and among Quoin, the Company and
the Holder, dated as of March 24, 2021, Quoin issued to the Holder a Series A warrant (as amended, “Series A Warrant”),
Series B warrant (as amended, “Series B Warrant”) and Series C warrant (as amended, “Series C
Warrant” and together with Series A Warrant and Series B Warrant, the “Primary Financing Warrants”),
which are exercisable to purchase American Depositary Shares (“ADSs”) of the Company.

 

B.          Pursuant
to the Securities Purchase Agreement (as amended, the “Bridge SPA”) by and between Quoin and the Holder, dated as of
March 24, 2021, Quoin issued to the Holder three series of warrants to purchase shares of Quoin's common stock, which were exchanged
for warrants to purchase ADSs of the Company on October 28, 2021 upon the consummation of the transactions contemplated pursuant
to that certain Agreement and Plan of Merger, dated as of March 24, 2021, by and among Quoin, the Company and CellMSC, Inc.,
a Delaware corporation and wholly owned subsidiary of the Company (as amended, collectively, the “Exchange Warrants”).

 

C.          Quoin,
the Company and the Holder entered into that certain Registration Rights Agreement, dated as of March 24, 2021 (as amended, the “RRA”).

 

D.          Quoin,
the Company and the Holder entered into that certain Waiver Agreement, dated as of June 6, 2022 (the “Waiver”
and together with the Primary Financing SPA, the Bridge SPA, the RRA, the Primary Financing Warrants and the Exchange Warrants, “Transaction
Documents”).

 

E.          Series B
Warrant was exercised in full, and Quoin, the Company and the Holder wish to further amend the Series A Warrant and the Exchange
Warrants, all as set forth herein.

 

F.          Upon
receipt by each party to this Agreement of this Agreement duly executed and delivered by such other parties to this Agreement, the amendments,
transactions and other provisions of this Agreement shall be effective as of the Effective Date.

 

NOW
THEREFORE, in consideration of the foregoing mutual premises and the covenants and agreements hereinafter set forth, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound hereby, agree as follows:

 

		1.	Amendments.

 

		(a)	As of the Effective Date, Section 1(b) of each of the Exchange Warrants and the Series A
Warrant is hereby amended and restated to read as follows:

 

“Exercise Price. For purposes
of this Warrant, “Exercise Price” means $0.00 per ADS.”

 

     

     

    

 

		(b)	As of the Effective Date, Section 2(k) of each of the Exchange Warrants and Section 2(d) of
the Series A Warrant is hereby amended and restated to read as follows:

 

“Change in ADS Ratio.
If after the Issuance Date the ratio of ADSs to Ordinary Shares is increased or reduced, then the number of Warrant Shares to be delivered
upon exercise of this Warrant will be proportionately adjusted.”

 

		(c)	Section 4(a), Purchase Rights, of each of the Exchange Warrants and Series A Warrant
is hereby deleted.

 

		2.	Exercise of Warrants. Subject to the provisions of Section 1(f) of the Series A
Warrant and Exchange Warrants (the “Blocker Provisions”), the Holder shall, within thirteen (13) Trading Days after
the Effective Date or as soon as practicable thereafter to enable the Holder to exercise without violating the Blocker Provisions, exercise:
(i) the Exchange Warrants for, and the Company shall issue and deliver to the Holder, 1,238,429 ADSs (as adjusted for any stock dividend,
stock split, stock combination reclassification or similar transaction relating to the ADSs or the Ordinary Shares underlying the ADSs
occurring after the Effective Date); and (ii) the Series A Warrant for, and the Company shall issue and deliver to the Holder,
3,761,571 ADSs (as adjusted for any stock dividend, stock split, stock combination reclassification or similar transaction relating to
the ADSs or the Ordinary Shares underlying the ADSs occurring after the Effective Date) (ADSs in (i) and (ii), collectively, the
 “Final ADSs”). The Company shall credit the Final ADSs, which shall not bear any restrictive legend, to the Holder's
or its designee's balance account with The Depository Trust Company (“DTC”) through its Deposit/Withdrawal At Custodian
system on or prior to the applicable Share Delivery Date.

 

		3.	Termination of Transaction Documents. The Holder acknowledges and agrees that effective upon the
Effective Date:

 

		(a)	the remaining outstanding Series A Warrant to purchase 514,681 ADSs is cancelled;

 

		(b)	Series C Warrant to purchase 2,389,670 ADSs is cancelled;

 

		(c)	the Company has no obligation to, and the Company will not, issue an additional Series A Warrant
and an additional Series B Warrant, each to purchase 2,389,670 ADSs (as adjusted for any stock dividend, stock split, stock combination
reclassification or similar transaction relating to the ADSs or the Ordinary Shares underlying the ADSs occurring after the Effective
Date); and

 

		(d)	any and all of the Company’s and/or Quoin’s other obligations, agreements, and covenants,
as applicable, under the Transaction Documents are terminated, and such Transaction Documents are null and void and are of no further
force or effect, provided, however, that the RRA shall remain in full force and effect with respect to the registration
for resale by the Holder of Ordinary Shares underlying the Final ADSs as Registrable Securities
thereunder in accordance with the terms thereof until such time as the Holder has sold such Ordinary Shares; provided, further,
that the Series A Warrant and Exchange Warrants, each as amended by the terms of this Agreement, shall remain in full force and effect
with respect to the Ordinary Shares underlying the Final ADSs until such time as the Holder has exercised such warrants in accordance
with Section 2.

 

		4.	Registration Statement. The Company hereby agrees that it shall not file any registration statement
with the Securities and Exchange Commission (other than on Form F-4 or Form S-8 (each as promulgated under the Securities Act
of 1933, as amended) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of
any entity or business or equity securities issuable in connection with the Company’s stock option or other employee benefit plans)
until the earlier of (i) thirteen (13) Trading Days after the Effective Date (such actual date of filing, the “Filing Date”),
and (ii) the date when the aggregate trading volume of ADSs on or after the Effective Date is equal to or exceeds 25 million ADSs
(as adjusted for any stock dividend, stock split, stock combination reclassification or similar transaction relating to the ADSs or the
Ordinary Shares underlying the ADSs occurring after the Effective Date) (the date described in this clause (ii), the “Suspension
Date”).

 

     

     

    

 

		5.	Lock Up. The Company may, at any time after the earlier of (i) the date that is ten (10) Trading
Days after the Filing Date, and (ii) the Suspension Date, and on no more than one (1) occasion, deliver a written notice (the
 “Lock-Up Notice” and the date the Holder receives the Lock-Up Notice, the “Lock-Up Notice Date”)
to the Holder instructing the Holder of the Lock-Up Period (as defined below). Such Lock-Up Notice may only be provided after 4:00 p.m. New
York City time on the Lock-Up Notice Date. The Holder hereby agrees not to sell, dispose or otherwise transfer, directly or indirectly
(including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or
short positions), ADSs or Ordinary Shares with respect to which the Holder has beneficial ownership within the rules and regulations
of the Securities and Exchange Commission during the Lock-Up Period. For the avoidance of doubt, the Holder will not be prohibited as
set forth herein in connection with the settlement of any sale of ADSs or Ordinary Shares for which the Holder has entered into a contract
for sale prior to the Holder's receipt of the Lock-Up Notice and for which the Holder has not yet settled. As used herein, “Lock-Up
Period” means the period beginning on 5:00 p.m., New York City time, on the Lock-Up Notice Date and ending by no later than
5:00 p.m., New York City time on the date that is twenty (20) Trading Days following the Lock-Up Notice Date.

 

		6.	Standstill. The Holder hereby agrees that neither the Holder nor any of its affiliates have any
right to participate in any future public or private offering of securities of the Company.

 

		7.	Representations and Warranties. The Holder represents and warrants to the Company and Quoin that
the Holder, and each of the Company and Quoin represents and warrants to the Holder that each of the Company and Quoin, as of the Effective
Date: (i) is an entity duly organized and validly existing under the laws of the jurisdiction of its formation, has the requisite
power and authority to execute and deliver this Agreement and to carry out and perform all of its obligations under the terms of this
Agreement; (ii) has duly executed and delivered on behalf of the applicable party this Agreement. The Holder and each of the Company
and Quoin represents and warrants, as of the Effective Date, that: (a) this Agreement, once executed and delivered by the parties,
constitutes the valid and legally binding obligation of the Holder and each of the Company and Quoin, as applicable, enforceable against
such person in accordance with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors' rights and remedies; and (b) the execution, delivery and performance by the applicable party of this Agreement and the
consummation by such person of the transactions contemplated hereby will not (i) result in a violation of the organizational documents
of such person, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or
instrument to which such person is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree
(including federal and state securities laws) applicable to such person, except in the case of clause (ii) and (iii) above,
for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a
material adverse effect on the ability of such person to perform its obligations hereunder.

 

		8.	Cleansing. The Company
hereby agrees to file with the Securities and Exchange Commission on or before 8:30 a.m., New York City time, on the first Trading Day
following the Effective Date, a Report of Foreign Private Issuer on Form 6-K (and attaching the form of this Agreement as an exhibit
to such filing (including all schedules and attachments), the “6-K Filing”), publically disclosing the transactions
as contemplated by this Agreement in accordance with applicable laws, rules and regulations. Immediately following the filing of
the 6-K Filing, the Holder shall not be in possession of any material, nonpublic information received from the Company, Quoin, any of
their respective Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, that is not disclosed in
the 6-K Filing. In addition, effective upon the filing of the 6-K Filing, each of Quoin and the Company acknowledges and agrees that any
and all confidentiality or similar obligations under any agreement, whether written or oral, between Quoin and/or the Company, any of
their respective Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the
Holder or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and
confirms that the Holder and its affiliates will rely on the foregoing representations in effecting transactions in securities of the
Company.

 

     

     

    

 

		9.	Miscellaneous.

 

		(a)	The Company shall reimburse
the Holder for its reasonable legal fees and expenses actually incurred in connection with the preparation and negotiation of this Agreement
and transactions contemplated hereby, by paying any such amount to Schulte Roth & Zabel LLP (the “Holder Counsel
Expense”) within two (2) Business Days of receiving the invoice of Schulte Roth & Zabel LLP by wire transfer of
immediately available funds in accordance with the written instructions of Schulte Roth & Zabel LLP. The Holder Counsel Expense
incurred in connection with the preparation and negotiation of this Agreement shall be paid by the Company whether or not the transactions
contemplated by this Agreement are consummated. Except as otherwise set forth above, each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement.

 

		(b)	Provisions of this Agreement may be amended and the observance thereof may be waived, only with the written
consent of all parties to this Agreement. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay
by a party in exercising such right or remedy, shall not operate as a waiver thereof.

 

		(c)	Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon
delivery, when sent by electronic mail (provided that the sending party does not receive an automated rejection notice); or (iii) two
days after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses
and e-mail addresses for such communications shall be as follows:

 

If to the Company
or Quoin:

Quoin Pharmaceuticals Ltd.

Azrieli Center, Round Tower, 30th Floor

132 Menachem Begin Blvd

Tel Aviv, 6701101

Attention: Michael Myers, Ph.D.

E-mail: mmyers@quoinpharma.com

 

With a copy (for
informational purposes only) to:

 

Blank Rome LLP

One Logan Square

130 North 18th Street

Philadelphia, PA

Attention: Yelena Barychev, Esq.

Email: yelena.barychev@blankrome.com

 

If to the Holder:

 

c/o Altium Capital
Management, LP

152 West 57th Street, 20th Floor

New York, NY 10019

Attention: Joshua Thomas

Telephone: 212-259-8404

E-mail: jthomas@altiumcap.com

 

     

     

    

 

With a copy (for informational purposes
only) to:

 

Schulte Roth &
Zabel LLP

919 Third Avenue

New York, New
York 10022

Telephone: (212)
756-2000

Facsimile: (212)
593-5955

Attention: Eleazer
Klein, Esq.

Email: eleazer.klein@srz.com

 

or to such other address, facsimile number
and/or email address to the attention of such other person as the recipient party has specified by written notice given to each other
party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of
such notice, consent, waiver or other communication, (B) electronically generated by e-mail transmission containing the time, date,
e-mail address or (C) provided by a courier or overnight courier service shall be rebuttable evidence of personal service or receipt
from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

		(d)	All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is
brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

		(e)	If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended
to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall
not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith
negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes
as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

		(f)	This Agreement constitutes the entire agreement among the parties hereto with respect to the subject matter
hereof and supersedes in their entirety all prior negotiations, understandings and agreements between the Company, any of its subsidiaries
or any of their respective shareholders, members, partners, officers, directors, managers, affiliates, employees or agents (collectively
 “Representatives”), on the one hand, and the Holder or any of its Representatives, on the other hand, whether written
or oral. There are no restrictions, promises, warranties or undertakings with respect to the subject matter hereof, other than those set
forth or referred to herein.

 

     

     

    

 

		(g)	This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

		(h)	The headings in this Agreement are for convenience of reference only and shall not limit or otherwise
affect the meaning hereof.

 

		(i)	This Agreement may be executed in identical counterparts, each of which shall be deemed an original but
all of which shall constitute one and the same agreement. This Agreement, once executed by a party, may be delivered via electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

		(j)	Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

		(k)	The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent and no rules of strict construction will be applied against any party.

 

[Signature Page Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have caused their respective signature pages to this Agreement to be duly executed as of
the Effective Date.

 

	 	COMPANY:
	 	 
	 	QUOIN PHARMACEUTICALS LTD.
	 	 	 
	 	 	 
	 	By:	
    /s/ Dr. Michael Myers

	 	 	Name:	Dr. Michael Myers
	 	 	Title: 	Chief Executive Officer

 

	 	QUOIN:
	 	 
	 	QUOIN PHARMACEUTICALS INC.
	 	 	 
	 	 	 
	 	By:	
    /s/ Dr. Michael Myers

	 	 	Name:	Dr. Michael Myers
	 	 	Title: 	Chief Executive Officer

 

     

     

    

 

IN
WITNESS WHEREOF, the parties have caused their respective signature pages to this Agreement to be duly executed as of
the Effective Date.

 

	 	HOLDER:
	 	 
	 	ALTIUM GROWTH FUND, LP
	 	 	 
	 	 	 
	 	By:	/s/ Mark Gottlieb
	 	 	Name:	Mark Gottlieb
	 	 	Title: 	COO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]